Skip to main content

Table 1 Eligibility criteria for the PRECOVID trial

From: Prevention of exacerbations in patients with COPD and vitamin D deficiency through vitamin D supplementation (PRECOVID): a study protocol

Inclusion criteria

Exclusion criteria

Vitamin D deficiency (serum 25(OH)D < 50 nmol/l)

Severe vitamin D deficiency (serum 25(OH)D <15 nmol/l),

Postbronchodilator FEV1/FVC < 0.70, FEV1 < 80 % and diagnosis COPD confirmed by a physician

Use of a supplement containing more than 400 IU vitamin D per day

Recent COPD exacerbation

Use of maintenance dose oral corticosteroids

≥10 packyears of smoking

Diagnosed asthma

Age ≥ 40 years

Diagnosed osteoporosis

Written informed consent

Self-reported history of hypercalcaemia or nephrolithiasis

Ability to comply with all study requirements.

Self-reported presence of sarcoidosis

 

Diagnosed chronic kidney disease stage 4 or higher (eGFR ≤ 29 ml/min/1.73 m2)

 

Interfering malignant diseases

 

Life expectation of less than 1 year on the basis of concurrent disease

 

Current participation in a clinical rehabilitation program

 

Pregnant or lactating women, or subjects who intend to become pregnant within the study period

 

Potentially unreliable patients and those judged by the investigator to be unsuitable for the study

 

Serious mental impairment i.e. preventing to understand the study protocol or comply with the study aim

  1. 25(OH)D 25-hydroxyvitamin D, FEV 1 Forced Expiratory Volume in one second, FVC Forced Vital Capacity, eGFR estimated Glomerular Filtration Rate with the MDRD formula